Kidney Outcomes in Patients with Systemic Lupus Erythematosus (SLE) Receiving Anifrolumab in the ASTER Real-World Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0814; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; P | "eGFR and UPCR remained in normal ranges and were preserved over 12M. These findings, while based on small numbers, suggest disease control with anifrolumab extends to renal manifestations in real-world care."
Clinical • Real-world • Real-world evidence • Chronic Kidney Disease • Immunology • Inflammatory Arthritis • Lupus • Renal Disease • Systemic Lupus Erythematosus
|
|
Julia Weinmann-Menke; Ioannis Parodis; Marta Mosca; Zahir Amoura; Mark Matsos; John Bell; Gelareh Atefi; Jonatan Natman; Parisa Karimi; Lyra Agustin
|